$ATNM Very Encouraging’ Results shown after 2 cycle of treatment with Actinium225 phase 1 non-metastatic castration-resistant prostate cancer. It’s matter of time when these companies realize the potentials ATNM. ⁦#astella ⁦@BayerUS⁩ $NVS $BMY $MRK  https://t.co/71W8vYjjJ1